These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 18467250

  • 1. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T, Dal Farra F, Ciliberti G, Pirina P, Guelfi R, Serra G, Paris R, Mancuso I, Cepparulo M.
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
    Kohno S, Tateda K, Mikamo H, Kadota J, Niki Y, Itamura R.
    J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
    [Abstract] [Full Text] [Related]

  • 3. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S, Yanagihara K, Yamamoto Y, Tokimatsu I, Hiramatsu K, Higa F, Tateyama M, Fujita J, Kadota J.
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study.
    Kuzman I, Daković-Rode O, Oremus M, Banaszak AM.
    J Chemother; 2005 Dec; 17(6):636-42. PubMed ID: 16433194
    [Abstract] [Full Text] [Related]

  • 5. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.
    Geckler RW.
    Clin Ther; 1994 Dec; 16(4):662-72. PubMed ID: 7982254
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
    Paris R, Confalonieri M, Dal Negro R, Ligia GP, Mos L, Todisco T, Rastelli V, Perna G, Cepparulo M.
    J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
    [Abstract] [Full Text] [Related]

  • 7. Ampicillin/sulbactam for children hospitalized with community-acquired pneumonia.
    Tapısız A, Özdemir H, Çiftçi E, Belet N, Ince E, Doğru Ü.
    J Infect Chemother; 2011 Aug; 17(4):504-9. PubMed ID: 21258955
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial.
    Rubio FG, Cunha CA, Lundgren FL, Lima MP, Teixeira PJ, Oliveira JC, Golin V, Mattos WL, Mählmann HK, Moreira ED, Jardim JR, Silva RL, Silva PH.
    Braz J Infect Dis; 2008 Jun; 12(3):202-9. PubMed ID: 18833404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.
    Treat Respir Med; 2004 Jun; 3(5):329-36. PubMed ID: 15606222
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S, Tateda K, Kadota J, Fujita J, Niki Y, Watanabe A, Nagashima M.
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.